Difference between revisions of "Cyclophosphamide (Cytoxan)"
Jump to navigation
Jump to search
m |
m |
||
Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
− | |||
*[[Adult T-cell leukemia-lymphoma]] | *[[Adult T-cell leukemia-lymphoma]] | ||
*[[Anaplastic large cell lymphoma]] | *[[Anaplastic large cell lymphoma]] | ||
+ | *[[B-cell acute lymphoblastic leukemia]] | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
*[[Bone cancer]] | *[[Bone cancer]] | ||
Line 20: | Line 20: | ||
*[[Coagulopathies]] | *[[Coagulopathies]] | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
+ | *[[Ewing's sarcoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
+ | *[[Glioblastoma]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
Line 31: | Line 33: | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
*[[Neuroendocrine tumors]] | *[[Neuroendocrine tumors]] | ||
+ | *[[Osteosarcoma]] | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
*[[Plasma cell leukemia]] | *[[Plasma cell leukemia]] | ||
+ | *[[Post-transplant lymphoproliferative disorder]] | ||
*[[Primary mediastinal B-cell lymphoma]] | *[[Primary mediastinal B-cell lymphoma]] | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
+ | *[[T-cell acute lymphoblastic leukemia]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
*[[Transformed lymphoma]] | *[[Transformed lymphoma]] | ||
Line 123: | Line 128: | ||
[[Category:Nitrogen mustards]] | [[Category:Nitrogen mustards]] | ||
− | |||
[[Category:Adult T-cell leukemia-lymphoma medications]] | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
[[Category:Anaplastic large cell lymphoma medications]] | [[Category:Anaplastic large cell lymphoma medications]] | ||
+ | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
[[Category:Bone cancer medications]] | [[Category:Bone cancer medications]] | ||
Line 135: | Line 140: | ||
[[Category:Coagulopathy medications]] | [[Category:Coagulopathy medications]] | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
+ | [[Category:Ewing's sarcoma medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
+ | [[Category:Glioblastoma medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
Line 146: | Line 153: | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
+ | [[Category:Osteosarcoma medications]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
[[Category:Plasma cell leukemia medications]] | [[Category:Plasma cell leukemia medications]] | ||
+ | [[Category:Post-transplant lymphoproliferative disorder medications]] | ||
[[Category:Primary mediastinal B-cell lymphoma medications]] | [[Category:Primary mediastinal B-cell lymphoma medications]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
− | [[Category:T-cell | + | [[Category:T-cell acute lymphoblastic leukemia medications]] |
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
[[Category:Transformed lymphoma medications]] | [[Category:Transformed lymphoma medications]] |
Revision as of 13:09, 21 July 2017
General information
Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference; n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Bladder cancer
- Bone cancer
- Breast cancer
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- CNS lymphoma
- Coagulopathies
- Diffuse large B-cell lymphoma
- Ewing's sarcoma
- Follicular lymphoma
- Glioblastoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Large granular lymphocytic leukemia
- Light-chain (AL) amyloidosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- Osteosarcoma
- Peripheral T-cell lymphoma
- Plasma cell leukemia
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Prostate cancer
- Small cell lung cancer
- T-cell acute lymphoblastic leukemia
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Waldenström macroglobulinemia
Patient drug information
- Cyclophosphamide (Cytoxan) patient drug information (Chemocare)[3]
- Cyclophosphamide (Cytoxan) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/16/1959: initial FDA approval
Also known as
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Alkyloxan | Biodoxan | Carloxan | Ciclofosfamida | Ciclofosfamida Filaxis | Ciclofosfamida Martian | Ciclokebir | Cyclam |
Cycloblastin | Cycloblastine | Cyclo Cell | Cycloferon | Cyclomide | Cyclophar | Cyclophospham | Cyclophosphamid |
cyclophosphamide monohydrate | Cyclophosphamid Farmos | Cyclophosphan | Cyclophosphan Lens | Cyclostin | Cycloxan | Cycram | Cydoxan |
Cyklofosfamid | Cytophosphan | Cytoxan | Cytoxan Lyophilized | Endoxan | Endoxan-N | Endoxana | Endoxan Asta |
Formitex | Genoxal | Genuxal | Hidrofosmin | Ledoxan | Ledoxina | Lyophilized Cytoxan | Neosar |
Oncomide | Oncophos | Procytox | Revimmune | Sendoxan | Syklofosfamid | Trav Cyclophosphamide | Tymtran |
Zycram |
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Irritant chemotherapy
- Neutral chemotherapy
- Oral chemotherapy
- Alkylating agents
- Nitrogen mustards
- Adult T-cell leukemia-lymphoma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Coagulopathy medications
- Diffuse large B-cell lymphoma medications
- Ewing's sarcoma medications
- Follicular lymphoma medications
- Glioblastoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Large granular lymphocytic leukemia medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Osteosarcoma medications
- Peripheral T-cell lymphoma medications
- Plasma cell leukemia medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Small cell lung cancer medications
- T-cell acute lymphoblastic leukemia medications
- Thymoma medications
- Transformed lymphoma medications
- Transplant medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1959
- WHO Essential Cancer Medicine